Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Tokai University School of Medicine, Isehara, Japan

Survival: 17.8 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Japan
City/State/Province: Isehara
Hospital: Tokai University School of Medicine
Journal: Link
Date: 11/2010

This phase 2 study involved 62 women with metastatic breast cancer who had previously been treated with anthracycline and taxane drugs. The median age of the group was 53 years with a range of 25-74.

Patients in this study were treated with the chemotherapy agent gemcitabine.

One patient died of acute respiratory failure during this study. In addition, 58.1% of patients experienced grade 3 or 4 neutropenia. Anorexia and malaise (any grade) was reported by 45.2% of patients.

The median overall survival reported in this study was 17.8 months.

This study was funded by Eli Lilly, makers of gemcitabine (brand name: Gemzar).

Correspondence: Dr. Yasuhiro Suzuki; email:

E-mail to a Friend Email Physician More Information